Enfamil maker vows to fight $60 million baby-formula verdict as stock slides
By Claudia Assis
Reckitt said it 'stands behind' its Mead Johnson baby formula
Reckitt Beckinser Group said Friday it will seek to overturn a court ruling this week that awarded $60 million in damages to the family of a baby that died after being fed Enfamil infant formula, made by the British conglomerate's Mead Johnson Nutrition unit.
U.S.-listed shares of Reckitt (UK:RKT) (RBGLY) fell 14% on Friday, while shares of Abbott Laboratories (ABT) dropped more than 5%. Abbott, too, is involved in litigation regarding its Similac brand of baby formula.
A nationwide baby-formula shortage sent parents scrambling in 2022, mostly because of product recalls earlier that year involving contamination concerns at an Abbott plant.
In a statement Friday, Reckitt said it stood by "the safety of our products" and that it rejected court findings that its product caused a serious gastrointestinal problem in the baby.
"It is important to note that this is a single verdict in a single case and should not be extrapolated," the company said. "We are, of course, surprised and deeply disappointed with the verdict and will pursue all options to have it overturned."
Thousands of baby-formula-related lawsuits are making their way through the courts currently. In a February filing, Abbott said that it is a defendant in 993 lawsuits pending in federal and state courts relating to preterm babies being fed cow's-milk-based formulas. Some cases also stem from the alleged contamination at Abbott's plant.
The U.S. Food and Drug Administration in August sent warning letters to three baby-formula makers as part of what the agency called enhanced oversight of the product following the 2022 recalls and shortages.
Reckitt's American depositary receipts have lost 18% in the past 12 months, while Abbott shares have gained 16% over the same period. That compares with an advance of around 32% for the S&P 500 index SPX in the last 12 months.
-Claudia Assis
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-15-24 1540ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now